Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So for instance if BP bought Relief for 25 billion (just to keep the numbers easy to figure), a likely scenario would be we are issued shares in the BP company. In order to figure out how many, they would calculate our position at $10 a share (25b buyout ÷ 2.5b os = $10/share) and give us that dollar value in shares in the new company?
I've posted about a few of Javitt's companies that were acquired in the past and someone earlier today posted about a possible scenario where Javitt/Relief would sell and then this post referencing a buyout.
Can someone who has had a position in a stock, during a buyout, briefly describe what the scenarios would be in a buyout for us as shareholders? Ie: would we just be paid a per-share amount and then we're out? Would there be a stock swap of shares in the BP company issued for our shares? Would the share price immediately rise to the buyout amount and we keep our shares?
Wow. .534 and climbing. Woohoo. Hope it continues. If they can keep it up (aviptadil joke there), we will gap up nicely. They are above us now, without converting to usd.
I think it's just heavy sell orders because it did the same thing on Monday.
Trading halt message on the six. Last time it did this there were so many orders input that it clog their system for a few minutes on open. Usually does not show halted in red before opening.
https://www.cnbc.com/quotes/?symbol=RLF-CH
Chart is in real time but the numbers posted above are 15 minute delayed
Point: people are expecting $20/share on EUA. Not happening in my mind due to the limited use. If it's $5, I'll be thrilled, but may only be $1.50. While it may be obvious to you and I, I don't think some others get it.
But unfortunately, I don't think they are enrolling in these harder hit areas.
My point was they included that for a reason. I never drew a conclusion one way or the other. Nothing is in these PR's by chance.
In certain areas it's easing making it harder to enroll and in other areas it's might not be. I just included my firsthand experience to show why enrolling has slowed. I personally think covid will keep ebbing and surging in different areas.
I'm surprised no one has mentioned this one sentence at the end of the first paragraph of this morning's PR:
GENEVA and RADNOR, Pa., Sept. 30, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. have established supply chain agreements and ordered sufficient drug substance (RLF-100TM) to prepare to treat 1 million patients with COVID-19, should the pandemic continue.
Should the pandemic continue.
Recently had to go to the Hospital ER, here in the north Houston area, Memorial Hermann is the name, with my wife that had gotten bitten by a neighbor's dog. While checking in to an empty ER (which normally has 400 people in it), my wife asked the nurse how busy they had been in relation to covid. The nurse told her they've been sending nurses home, "cutting them", because the hospital was so empty. There was literally no one else in the ER, while we were there, and that's a first. That's why it's been hard to enroll those last patients.
Another reason is, almost every hospital is doing some sort of a trial now. Lots of competition. Not trying to say that covid-19 isn't real, but I do think the media has blown it out of proportion in certain areas. Houston was recently supposedly one of the hardest hit cities, but yet this major hospital is empty. I think most of these numbers are not showing that these people are being treated at home or in nursing homes and are not in the icu.
As I've been saying all along, Relief is catering to a niche group. Dr. Javitt reiterated that today by saying the EUA application was only for the sickest of the sick, in the ICU, after all available treatment options have been exhausted. That's very few. In all likelihood, these numbers could continue decreasing over time, hence the last sentence about the pandemic continuing up above.
I still believe in this company, and Dr. Javitt has been very forthright at all steps, however as I've been saying, we all need to temper our enthusiasm a little bit, when it comes to the price per share jump everyone is anticipating and the timeline. Remember Ram has stated this company has the potential to bring in hundreds of millions a year. He didn't say billions, he said millions. Andy Harris stated in the 9/24 video, that this has the potential to save tens of thousands of lives. He didn't say hundreds of thousands or millions. And Dr. Javitt did not say the FDA will take 30 or 60 days, like some on here have said, he said he had heard that they try to respond in 30 to 60 days. Obviously with Remdesivir, we know they submitted on April 8th and were approved on May 1st. But I think RAM and Dr. Javitt have been very honest and subdued stating numbers and timeline and I appreciate that. Would much rather have that than a pumper.
My point to all this is, they've been giving us little clues all along, that timelines sometimes get extended and hinting that we need to temper our enthusiasm a smidgen, to keep our expectations closer to reality. The sell-off was obviously due to huge disappointment, because the sellers had too high of expectations to start with.
In summary, Dr. Javitt did mention the investors in the company and acknowledged
they should be rewarded for helping the drug get to where they were. I also appreciate that. Is this a 20 bagger? Maybe, in a few steps, but most likely not on EUA day at the first step. Be patient, it'll come, but if you can't wait, then sell. And when it comes, it will come in steps. EUA. Nasdaq uplist. Full approval. Large orders by Governments. Inhaler. Approval for other illnesses. All at different times. And lastly, keep in mind this pandemic could ease on it's own. Hopefully we get through these steps quickly and can be the ones that eradicate it.
New PR.
GENEVA and RADNOR, Pa., Sept. 30, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. have established supply chain agreements and ordered sufficient drug substance (RLF-100TM) to prepare to treat 1 million patients with COVID-19, should the pandemic continue.
RLF-100™ is still in FDA-approved phase 2b/3 clinical trials for the treatment of critical COVID-19 in the US. A readout by the study's Data Monitoring Committee is expected within the next month. European trials with RLF-100TM are in preparation and are scheduled to start in Q1 2021.
The development partners, NeuroRx and Relief, are leading US and EU commercialization plans, respectively. They have now contracted with Nephron Pharmaceuticals, Inc. to manufacture commercial supplies of RLF-100™, in order to ensure that adequate drug inventory will be immediately available, should the clinical trials demonstrate safety and efficacy.
NeuroRx and Relief have similarly contracted with Bachem Americas (www.bachem.ch) to manufacture sufficient RLF-100TM drug substance to treat 1 million patients. Bachem was the first peptide manufacturer to synthesize RLF-100TM and has played a leading role in the development of the drug substance over the past 20 years.
NeuroRx and Relief have additionally contracted with a leading nationwide pharmaceutical logistics partner in order to ensure overnight supply to US hospitals, should RLF-100™ continue to succeed in clinical trials.
"In normal circumstances, it would be prudent to wait until all the data are in before initiating commercial scale-up. However, in an environment where more than 40,000 Americans are contracting COVID-19 daily and 800 are dying each day, there is not a moment to lose in ensuring that sufficient quantities of RLF-100™ will be available, should the clinical trials succeed in proving safety and efficacy," said Dr. Jonathan Javitt, CEO and Chairman of NeuroRx, Inc.
Dr. Raghuram (Ram) Selvaraju, Chairman of the Board of Relief continued: "We are living in unprecedented times, which call for flexibility and innovative thinking, in and outside the clinic. Therefore, we have taken the necessary steps to match the rapid clinical development of RLF-100TM by establishing a supply chain capable of scaling up to meet the urgent medical needs of critical COVID-19 patients."
About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, which is critical to the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by Respiratory Failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression. (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
About RLF-100
RLF-100 (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100 for the treatment of COVID-19 and awarded Fast Track designation. RLF-100 is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization for treatment of individual patients, and an Expanded Access Protocol IND authorization for the treatment of respiratory failure in COVID-19.
About RELIEF THERAPEUTICS Holding AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE NeuroRx
https://www.prnewswire.com/news-releases/neurorx-and-relief-therapeutics-establish-supply-and-distribution-agreements-for-rlf-100-aviptadil-301140389.html
You're certainly welcome. I'm just glad I'm off for a few days, because my whole life has been staying up till at least 2:30a Central to see the Swiss open (sometimes til 3-3:30, and waking up at 8:15a Central to get ready for our Market open. Then napping in the middle of the day to add to my only 5 hrs of sleep. I don't know how people that have a demanding job stay up with this. Lol. This stock is wearing me out.
Post 23715 from tiggerifficm4.
https://mobile.twitter.com/YoDoctorYo/status/1311129500520939524?s=20
Wow! Nice job. Looks like you have put a lot of time into this and looks very logical. I did have a few questions. Where does the 5,750,000,000 figure on the lower right of the main sheet come from? Is that supposed to be 5b even for current inventory? Secondly, the 25.5 market cap in blue, where does that come from?
Not to nitpick, but a few typos jumped out at me. OTCQB page label is misspelled. On that same page, "closing" is spelled wrong also. Those are the only things that jumped out at me. Outstanding work!!
Oh. I thought the 940k order was a one time order.
Revenue multiples are for ongoing sales figures right? Not a one-time sale.
I vaguely remember Dr Javitt or Ram saying about 10,000/treatment, so I just used that, because it's easy to figure. You may be right that 8000 is more reasonable. My methodology was 940k x 10000 ÷ 2 (relief's cut) ÷ 2.5b = $1.88/share. At 8k, it would be closer to $1.50, but regardless the emotional factor would amplify that news 10 fold.
That one order would be worth $1.88/share alone, not including the emotional bump which would be substantial.
Agreed "if" you sell all those courses. And that brings in a beautiful point that if the US government decides to pre-buy in mass, like they have pre-purchased 100's of millions of vaccines, then you can throw these numbers in the trash and the share price could "Kodak" 20x-40x on that alone.
Did I just start using a new verb?
I agree with your comparable also. A 4x-10x run is a reasonable expectation at first.
In my mind, this is a multi-step play. First step is EUA and getting to a Nasdaq price point. 2nd is getting uplisted. 3rd is full approval and therefore raking in all the $$$$$ the Robinhooders give us. 5th is retiring on the inhaler sales.
Selling at near highs and buying back on the corrections would pull in even more.
Million dollar question, that I am still unsure of. On the one hand I believe in the science and the Mgmt team, but Ram has said he thinks potential profits could be in the hundreds of millions annually (most on here are predicting billions, but he has to know more than they do), and secondly even Andy Harris has said he thinks this drug could potentially save the lives of tens of thousands. Which means there's going to be a whole lot of product left on the shelves. Remember this first approval is for a niche market, and not for everyone.
So will it go up substantially? I'm thinking like a 90% chance of that. But the million dollar question is how much and I don't think anyone, even professional analysts can predict that. To be honest this one could keep running every couple of months, with new news, Nasdaq uplist, inhaler, etc.
This doesn't help, but I'm thinking anywhere from $1.50 to $15 on the EUA approval before correction, with $6 being a good midpoint in my mind. There are just too many variables to accurately predict.
Hahahaha.
NeuroRx CEO and chairman Jonathan Javitt said: “We at NeuroRx are enormously appreciative of the FDA’s commitment to accelerating the development of any potential treatment for Covid-19. We hope to live up to the trust that has been placed in us by bringing a life-saving treatment to patients.”
Reminding the FDA of their mandate to rush, while they wait for a decision?
Giving a big pre-"thank you" to the FDA for approving it so quickly?
Reminding the FDA that they are sincerely thankful to them for all that they do? (A little brown nosing never hurts while you're waiting for a decision.)
Giving the FDA heads a backdoor, after their fast approval is attacked by the media, BP or those attacking Trump? Ie: we had to approve it so fast because we committed to the American people to do so for all potential therapies/treatments.
Take your pick.
Aren't you supposed to be out?
My ticker is saying that there's only been 7.7 million for the whole trading day??
Currently watching the Trump presser and he and the Governor of Mississippi are speaking about giving millions of covid testing kits to black colleges in Miss. that might not have the financial resources to purchase testing kits for their mainly black populations. The more that I think about it, over the last week Trump has been speaking a lot about minorities, obviously trying to grab a little bit of market share with the black vote.
My first reaction when I read the EUA application speaking about people of color and those of lower socioeconomic status not having access to covid treatments was "what does that have to do with approval"? But now I realize what an absolute stroke of genius for Javitt to have the foresight to include mention of minorities in the EUA application. Javitt is always like five moves ahead of everyone.
Almost seems that Javitt is in perfect sync with the Trump administration's talking points and may be communicating with them?
Now that the Gem deal is done, and it's most likely good PR's from here on out, I see the pps getting bolder and bolder in anticipation of an EUA PR. Do you think it'll trade sideways until then or climb slowly?
I think most of us would agree we expect the EUA inside of three weeks from the 9/17. Iow, last week when we found out the EUA application was already a week old, anyone could say there's a 1 in 14 chance of getting the EUA in the next two weeks on any given day. Now with each day going by without it, the odds are exponentially increased for the remaining days to be "the day".
I think if it doesn't come this week, the spring will be as tightly wound as it could possibly be by Monday, and has to move up in anticipation.
Jane has been camped out here for a while.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158455845
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158472048
Damn. Like Beetlejuice, somebody made the mistake of saying his name out loud recently and he reappears.
And you do realize that he didn't trade anything, he just exercised his options, right?
Do you honestly think the guy that started this company and ran it up until a year ago is not in the know? He has options which means he is an insider and would get this info before the market does.
And yet the Swiss are only down a penny and we are gonna open only down 2 pennies. Why are you only a doom n gloomer?
Of course I noticed that date, but where you see shady, I see he knows EUA is coming and wants to be ready to sell at the peak. Huge move of confidence.
Relief co-founder and ex-ceo from 2013-2019 has exercised 16,375,998 shares on 9/17/20. He knows where this is going too.
https://ch.linkedin.com/in/gaelhedou
https://www.ser-ag.com/en/resources/notifications-market-participants/significant-shareholders.html?companyId=MONDCH#/shareholder-details/TAK9L00065
I don't see an 8% dilution. I see a 1.8% dilution. Previous OS was 2,534,168,581. New OS is 2,580,068,581. Difference is 45,900,000. 45,900,000 new shares ÷ 2,534,168,581 old # of shares = .018, or 1.8% dilution.
Know what the best part of this PR is? It kills the "No news during Yom Kippur" theory. EUA could come at any time. Even during Yom Kippur. Be ready!
I see it as good overall. There has been a big worry about R/S and this signals to me, that it's unnecessary. They have plenty of $ to continue their trials and we already knew about their agreement with Gem. I would rather see this, than a R/S or them borrowing $......
...unless you're a flipper. Lmao
Who knows? Whenever I think it's heading to green, it doesn't. Whenever I get ready for red, it doesn't. I'm probably the only person that will admit I have no clue with this particular company. Lol
Sounds like this could be the final tranche though, besides the additional 6m they just authorized, so I guess that's good. And to be fully funded until 2022 with no debt is awesome. What this does to share price? Who knows? Perhaps one last buying opportunity before EUA?
New PR
Company Announcements
Pierrel SpA
EQS-News: Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
Twitter
Facebook
LinkedIn
GooglePlus
Pinterest
15 MINUTES AGOSource: EQS
EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Capital Increase
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
28.09.2020 / 07:00
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
Geneva, Switzerland, September 28, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced a capital increase pursuant to a drawdown of its Share Subscription Facility (SSF) with the Company's main shareholder GEM Global Yield Fund LLC SCS ("GEM").
Funds raised amount to CHF 17,949,600. The available cash on the balance sheet of the Company, after receipt of the funds, will be approximately CHF 48,000,000 and will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief believes that with the conclusion of this raise, its capital resources will be sufficient to support its planned operations through 2022, without taking into account potential revenues generated from sales of RLF-100. Execution of the SSF, together with the latest exercises of stock options, will bring the total amount of shares outstanding to 2,580,068,581.
Relief and GEM have agreed on an amendment to the SSF to increase the remaining balance by CHF 6,000,000 before the conclusion of this tranche. This action concludes the existing SSF and Relief has no plans to put a new one in place.
"We are now well funded to progress all ongoing and planned RLF-100 trials for COVID-19 indications and are on course to reach our next milestones. In the midst of the largest health crisis of our time, we remain committed to doing our part to ensure that as many patients as possible can quickly benefit from this potentially life-saving therapeutic option," said Raghuram (Ram) Selvaraju, Chairman of the Board of Relief.
About Relief
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100 (aviptadil), synthetic vasoactive intestinal peptide (VIP), is being investigated in two placebo-controlled US Phase IIb/III clinical trials in respiratory deficiency due to COVID-19. RLF-100 is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19.
Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100.
RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
CONTACT
RELIEF THERAPEUTICS Holding SA
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com
FOR MEDIA INQUIRES:
MC Services AG
Anne Hennecke / Brittney Sojeva
Mail: relief@mc-services.eu
Tel.: +49 (0) 211-529-252-14
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
End of Media Release
Language: English
Company: Relief Therapeutics Holdings AG
Avenue de Sécheron 15
1202 Genève
Switzerland
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Listed: SIX Swiss Exchange
EQS News ID: 1136765
End of News EQS Group News Service
1136765 28.09.2020
https://markets.ft.com/data/announce/detail?dockey=600-202009280100DGAP____CORPNEWS_corporate_1136765_en-1
Maybe the IRA vs margin acct is the difference. Hopefully this week we'll have a lot more to talk about than $15 fees. Lol